In the third installment of our series on primary progressive aphasia (PPA), Dr. Rogan Magee discusses nonfluent/agrammatic PPA. Show citations: Grossman M, Seeley WW, Boxer AL, et al. Frontotemporal lobar degeneration. Nat Rev Dis Primers. 2023;9(1):40. Published 2023 Aug 10. doi:10.1038/s41572-023-00447-0 Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014. doi:10.1212/WNL.0b013e31821103e6 Santos-Santos MA, Rabinovici GD, Iaccarino L, et al. Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia. JAMA Neurol. 2018;75(3):342-352. doi:10.1001/jamaneurol.2017.4309 Mandelli ML, Lorca-Puls DL, Lukic S, et al. Network anatomy in logopenic variant of primary progressive aphasia. Hum Brain Mapp. 2023;44(11):4390-4406. doi:10.1002/hbm.26388 Putcha D, Erkkinen M, Daffner KR. Functional Neurocircuitry of Cognition and Cognitive Syndromes. In: Silbersweig DA, Safar LT, Daffner KR. eds. Neuropsychiatry and behavioral neurology: principles and practice. McGraw Hill; 2021. Accessed November 6, 2025. https://neurology.mhmedical.com/content.aspx?bookid=3007§ionid=253215676 Montembeault M, Brambati SM, Gorno-Tempini ML, Migliaccio R. Clinical, Anatomical, and Pathological Features in the Three Variants of Primary Progressive Aphasia: A Review. Front Neurol. 2018;9:692. Published 2018 Aug 21. doi:10.3389/fneur.2018.00692 Clark DG. Frontotemporal Dementia. Continuum (Minneap Minn). 2024;30(6):1642-1672. doi:10.1212/CON.0000000000001506
Dr. Alex Menze and Professor Hakan Cetin discuss the need to reevaluate the approach to diagnosing and treating seronegative myasthenia gravis. Show citations: Krenn M, Wagner M, Schuller H, et al. Screening for Congenital Myasthenic Syndromes in Adults With Seronegative Myasthenia Gravis Using Next-Generation Sequencing. Neurology. 2025;105(8):e214177. doi:10.1212/WNL.0000000000214177
Dr. Gregg Day and Professor Jonathan Rohrer discuss the significance of studying individuals at risk of developing genetic frontotemporal dementia, focusing on how early cognitive changes before symptoms appear can inform research and future therapeutic trials. Show citation: Russell LL, Bouzigues A, Convery RS, et al. Executive Function Deficits in Genetic Frontotemporal Dementia: Results From the GENFI Study. Neurol Genet. 2025;11(4):e200248. Published 2025 Jul 21. doi:10.1212/NXG.0000000000200248
In the second installment of our series on primary progressive aphasia (PPA), Dr. Rogan Magee discusses logopenic PPA. Show citations: Grossman M, Seeley WW, Boxer AL, et al. Frontotemporal lobar degeneration. Nat Rev Dis Primers. 2023;9(1):40. Published 2023 Aug 10. doi:10.1038/s41572-023-00447-0 Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014. doi:10.1212/WNL.0b013e31821103e6 Santos-Santos MA, Rabinovici GD, Iaccarino L, et al. Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia. JAMA Neurol. 2018;75(3):342-352. doi:10.1001/jamaneurol.2017.4309 Mandelli ML, Lorca-Puls DL, Lukic S, et al. Network anatomy in logopenic variant of primary progressive aphasia. Hum Brain Mapp. 2023;44(11):4390-4406. doi:10.1002/hbm.26388 Putcha D, Erkkinen M, Daffner KR. Functional Neurocircuitry of Cognition and Cognitive Syndromes. In: Silbersweig DA, Safar LT, Daffner KR. eds. Neuropsychiatry and behavioral neurology: principles and practice. McGraw Hill; 2021. Accessed November 6, 2025. https://neurology.mhmedical.com/content.aspx?bookid=3007§ionid=253215676 Montembeault M, Brambati SM, Gorno-Tempini ML, Migliaccio R. Clinical, Anatomical, and Pathological Features in the Three Variants of Primary Progressive Aphasia: A Review. Front Neurol. 2018;9:692. Published 2018 Aug 21. doi:10.3389/fneur.2018.00692 Clark DG. Frontotemporal Dementia. Continuum (Minneap Minn). 2024;30(6):1642-1672. doi:10.1212/CON.0000000000001506
In the first part of this series, Dr. Rogan Magee provides an introduction to primary progressive aphasia (PPA) and explains its three subtypes. Show citations: Grossman M, Seeley WW, Boxer AL, et al. Frontotemporal lobar degeneration. Nat Rev Dis Primers. 2023;9(1):40. Published 2023 Aug 10. doi:10.1038/s41572-023-00447-0 Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014. doi:10.1212/WNL.0b013e31821103e6 Santos-Santos MA, Rabinovici GD, Iaccarino L, et al. Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia. JAMA Neurol. 2018;75(3):342-352. doi:10.1001/jamaneurol.2017.4309 Mandelli ML, Lorca-Puls DL, Lukic S, et al. Network anatomy in logopenic variant of primary progressive aphasia. Hum Brain Mapp. 2023;44(11):4390-4406. doi:10.1002/hbm.26388 Putcha D, Erkkinen M, Daffner KR. Functional Neurocircuitry of Cognition and Cognitive Syndromes. In: Silbersweig DA, Safar LT, Daffner KR. eds. Neuropsychiatry and behavioral neurology: principles and practice. McGraw Hill; 2021. Accessed November 6, 2025. https://neurology.mhmedical.com/content.aspx?bookid=3007§ionid=253215676 Montembeault M, Brambati SM, Gorno-Tempini ML, Migliaccio R. Clinical, Anatomical, and Pathological Features in the Three Variants of Primary Progressive Aphasia: A Review. Front Neurol. 2018;9:692. Published 2018 Aug 21. doi:10.3389/fneur.2018.00692 Clark DG. Frontotemporal Dementia. Continuum (Minneap Minn). 2024;30(6):1642-1672. doi:10.1212/CON.0000000000001506
In this episode of the Neurology Minute, Dr. Nara Miriam Michaelson delves into another women's history minute to discuss Sylvia Lawry.
Dr. Jason Crowell and Dr. YuHong Fu discuss the importance of differentiating between dementia with Lewy bodies and Parkinson disease dementia. Show citatiion: Fu Y, Halliday GM. Dementia with Lewy bodies and Parkinson disease dementia - the same or different and is it important?. Nat Rev Neurol. 2025;21(7):394-403. doi:10.1038/s41582-025-01090-x
Dr. Dan Ackerman and Dr. Isabel Hostettler discuss the diagnosis, risk factors, and prognosis of RCVS, highlighting the need to recognize symptoms and distinguish it from other causes of subarachnoid hemorrhage. Show reference: Hostettler IC, Ponciano A, Wilson D, et al. Outcomes After Reversible Cerebral Vasoconstriction Syndrome With Convexity Subarachnoid Hemorrhage: Individual Patient Data Analysis. Neurology. 2025;105(5):e213984. doi:10.1212/WNL.0000000000213984
In the November episode of the President's Spotlight, Dr. Jason Crowell talks with Dr. Natalia Rost about the Centers for Medicare & Medicaid Services final rule for how physicians are reimbursed in 2026. Show reference: https://www.aan.com/about-the-aan/presidents-spotlight
Dr. Aaron Zelikovich discusses a recent article on nipocalimab and its role in treating generalized myasthenia gravis. Show citations: Antozzi C, Vu T, Ramchandren S, et al. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025;24(2):105-116. doi:10.1016/S1474-4422(24)00498-8
Dr. Katherine Havard Coiro discusses the 2024 McDonald Criteria for Multiple Sclerosis and how to interpret cerebrospinal fluid. Show reference: Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Montalban, Xavier, et al. The Lancet Neurology, Volume 24, Issue 10, 850 - 865
In this episode of the Neurology Minute, Dr. Alison Christy delves into another women's history minute to discuss Marcelle Lapicque.
Dr. Alison Christy and Dr. Matthew Ryan Woodward discuss the complexities of status epilepticus, focusing on its definitions, the transition to refractory and super-refractory states, and the implications for treatment. Show citation: Woodward MR, Brown JP, Kittner SJ, et al. Super-Refractory Status Epilepticus Diagnosis, Management, and Prognostication: An International Survey Study. Neurol Clin Pract. 2025;15(5):e200520. doi:10.1212/CPJ.0000000000200520
In the second part of this two-part series, Dr. Bradley Ong explains the four clinical phases of a typical migraine attack. Show citation: Lipton RB, Stokes J, Evans CJ, et al. Characterizing the patient experience during the prodrome phase of migraine: A qualitative study of symptoms and their timing. Headache. 2025;65(8):1355-1368. doi:10.1111/head.15024
In part one of this two-part series, Dr. Bradley Ong discusses the prodrome phase of migraine and how it represents the earliest stage of the attack. Show citation: Lipton RB, Stokes J, Evans CJ, et al. Characterizing the patient experience during the prodrome phase of migraine: A qualitative study of symptoms and their timing. Headache. 2025;65(8):1355-1368. doi:10.1111/head.15024
In part two of this series, Dr. Stacey Clardy and Dr. Sandra Vukusic discuss gender disparities in the treatment of multiple sclerosis. Show citation: Gavoille A, Leray E, Marignier R, et al. Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis. Neurology. 105(4) e213907. doi:10.1212/WNL.0000000000213907
In part one of this two-part series, Dr. Stacey Clardy and Dr. Sandra Vukusic discuss what disease-modifying therapies can be safely continued and strategically timed when pregnancy is anticipated. Show citation: Gavoille A, Leray E, Marignier R, et al. Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis. Neurology. 105(4) e213907. doi:10.1212/WNL.0000000000213907
Dr. Alison Christy and Dr. Jennifer L. McGuire discuss neuroimaging findings linked to ICANS, exploring whether specific imaging patterns correlate with distinct neurologic symptoms. Show citation: McGuire JL, Pinto S, Erdogan EN, et al. Neuroimaging Findings in Children and Young Adults With Neurotoxicity After CAR T-Cell Therapy for B-Cell Malignancies. Neurology. 2025;105(7):e214086. doi:10.1212/WNL.0000000000214086
In the final episode of this three-part series, Dr. Jeff Lambe addresses practical considerations surrounding the inclusion of the optic nerve as a topography for demonstrating dissemination in space. Show citation: Montalban X, Lebrun-Frénay C, Oh J, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. 2025;24(10):850-865. doi:10.1016/S1474-4422(25)00270-4
In part two of this three-part series, Dr. Jeff Lambe outlines how the optic nerve is being incorporated as one of five topographies used to demonstrate dissemination in space. Show citation: Montalban X, Lebrun-Frénay C, Oh J, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. 2025;24(10):850-865. doi:10.1016/S1474-4422(25)00270-4
Marie
Thank you for this news.
محمد💊
**ریتم شبانه روزی** ساعت داخلی ۲۴ ساعته بدن است که چرخه خواب-بیداری، ترشح هورمونها (مثل ملاتونین در شب و کورتیزول در صبح)، و عملکردهایی مانند متابولیسم را تنظیم میکند. این ریتم توسط **هسته سوپراکیاسماتیک** در مغز کنترل شده و با نور/تاریکی هماهنگ میشود. اختلال آن (با نور مصنوعی، جتلاگ یا شیفتکاری) باعث خستگی، بیخوابی، یا مشکلات متابولیک میشود. برای تنظیم آن، نور صبحگاهی، برنامه منظم خواب و پرهیز از محرکها پیش از خواب توصیه میشود. تفاوتهای فردی (مثل شبزنده دار یا سحرخیز بودن) نیز تحت تأثیر ژنهاست.